Roche drug success counteracted by franc

Swiss currency’s strength hits pharmaceutical group’s revenues

Diamond’s adventure with BancABC

Precious Ramotswe cautions Diamond in his African adventure

UK stem cell blood set for human trials

Scheme seen as viable for patient tests by late 2016

GSK denies systemic corruption problem

BBC report says Polish doctors bribed to promote asthma drug

Race for hepatitis C drugs accelerates

Scramble for share of market expected to reach $20bn in sales

Big pharma: Storehouse of trouble

A raft of lawsuits and probes has reinforced criticism that the industry puts profits before public health

Europe and Asia join in US tech rout

Internet and chip stocks hit as Nasdaq suffers worst fall since 2011

French probe alleged drug collusion

Roche and Novartis investigated over lucrative eye treatment

Scientists hit out at UK flu expenditure

Government accused of throwing away more than £600m

Price of hepatitis C drug attacked

WHO condemns $1,000-a-day price of Gilead Sciences’ treatment

Actos case floors Takeda and Eli Lilly

Case highlights temptation to conceal potential health risks

Takeda: a fine mess

Drug companies prove resilient in the face of large fines

Johnson aims to boost life sciences

Record $6bn fine for Takeda over diabetes drug

Japan group hid possible link between product and bladder cancer

Doubts emerge about ‘wonder drugs’

Glitazones for diabetes run into safety issues

Pharma reform should go beyond GSK

Risk is ‘zero tolerance’ for bad ways may be lost in translation

Tax thread runs through pharma deals

Appetite for ‘inversions’ rose after US plan to tighten domicile rules

Ranbaxy sale highlights Japan’s deal woes

Daiichi’s stake sale another example of soured cross-border deal

GSK investigates Iraq bribery claims

Accusations against drugmaker follow corruption concerns in China

Sun Pharma offers $3.2bn for Ranbaxy

Deal allows partial exit for Japan’s Daiichi Sankyo


More FT Twitter accounts